Valuation: Pharmigene, Inc.

Market Cap 363M 11.27M 9.77M 9.14M 8.34M 15.7M 1.07B 15.96M 107M 42M 538M 42.31M 41.39M 1.79B P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 933M 28.93M 25.07M 23.47M 21.42M 40.31M 2.76B 40.98M 275M 108M 1.38B 109M 106M 4.61B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 week+2.71%
Current month+2.71%
1 month+14.65%
3 months-26.53%
6 months-31.43%
Current year-27.27%
1 week 7.2
Extreme 7.2
7.2
1 month 5.9
Extreme 5.9
9.35
Current year 5.9
Extreme 5.9
11.85
1 year 5.9
Extreme 5.9
14.1
3 years 5.9
Extreme 5.9
24.6
5 years 5.9
Extreme 5.9
25.7
10 years 5.9
Extreme 5.9
36
Manager TitleAgeSince
Chief Executive Officer 67 03/11/2019
Chief Operating Officer 49 03/11/2019
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 35 03/11/2019
Director/Board Member 65 06/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.71%-38.98%-70.49% 11.27M
-0.24%+3.42%+108.97%+303.02% 4.05B
+0.30%0.00%+65.81%+84.53% 3.73B
+1.41%+48.85%+229.44%-8.07% 2.94B
+0.34%+0.30%+301.27%+430.67% 2.44B
+1.43%+5.85%-22.03%-29.93% 2.35B
+4.22%+6.51%+9.93% - 1.35B
+5.85%+16.46%+17.72%+46.95% 1.05B
-4.28%-9.64%+182.04%-43.81% 866M
+5.70%+10.67%-33.71%+0.79% 572M
Average +1.47%+16.83%+82.05%+79.30% 1.94B
Weighted average by Cap. +1.03%+23.38%+114.42%+139.49%

Financials

2024 2025
Net sales 117M 3.61M 3.13M 2.93M 2.68M 5.03M 345M 5.12M 34.38M 13.47M 173M 13.57M 13.27M 576M 200M 6.2M 5.37M 5.03M 4.59M 8.64M 591M 8.78M 58.97M 23.11M 296M 23.28M 22.77M 987M
Net income -82.86M -2.57M -2.23M -2.08M -1.9M -3.58M -245M -3.64M -24.45M -9.58M -123M -9.65M -9.44M -409M -73M -2.26M -1.96M -1.84M -1.68M -3.15M -216M -3.21M -21.54M -8.44M -108M -8.5M -8.32M -361M
Net Debt 458M 14.2M 12.31M 11.52M 10.51M 19.78M 1.35B 20.11M 135M 52.92M 678M 53.32M 52.15M 2.26B 570M 17.67M 15.31M 14.33M 13.08M 24.61M 1.68B 25.02M 168M 65.84M 843M 66.33M 64.88M 2.81B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
11/08/26 NT$7.200 0.00% 2,010
10/08/26 NT$7.200 0.00% 4,090
07/08/26 NT$7.200 0.00% 20
06/08/26 NT$7.200 0.00% 10
05/08/26 NT$7.200 +2.71% 26,030
  1. Stock Market
  2. Stocks
  3. 7595 Stock